Beam Therapeutics
NASDAQ · BEAM·Cambridge, MA·Mid-cap·Phase 2
Clinical-stage biotech pioneering base-editing therapies. Lead programs include BEAM-101 for sickle cell disease and BEAM-302 for AAT deficiency, with multiple in vivo and ex vivo base editing assets in development.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Beam Therapeutics Corporate Presentation | Corporate overview | April 15, 2026 | 27 |